Blood Journal
Leading the way in experimental and clinical research in hematology

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

  1. David S. Siegel1,*,
  2. Thomas Martin2,
  3. Michael Wang3,
  4. Ravi Vij4,
  5. Andrzej J. Jakubowiak5,
  6. Sagar Lonial6,
  7. Suzanne Trudel7,
  8. Vishal Kukreti7,
  9. Nizar Bahlis8,
  10. Melissa Alsina9,
  11. Asher Chanan-Khan10,
  12. Francis Buadi11,
  13. Frederic J. Reu12,
  14. George Somlo13,
  15. Jeffrey Zonder14,
  16. Kevin Song15,
  17. A. Keith Stewart16,
  18. Edward Stadtmauer17,
  19. Lori Kunkel18,
  20. Sandra Wear19,
  21. Alvin F. Wong20,
  22. Robert Z. Orlowski3, and
  23. Sundar Jagannath21
  1. 1 John Theurer Cancer Center at Hackensack University, Hackensack, NJ, United States;
  2. 2 University of California, San Francisco, CA, United States;
  3. 3 MD Anderson Cancer Center, Houston, TX, United States;
  4. 4 Washington University School of Medicine, St. Louis, MO, United States;
  5. 5 University of Chicago, Chicago, IL, United States;
  6. 6 Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, United States;
  7. 7 University of Toronto Princess Margaret Hospital, Toronto, ON, Canada;
  8. 8 Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada;
  9. 9 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, United States;
  10. 10 Mayo Clinic, Jacksonville, FL, United States;
  11. 11 Mayo Clinic, Rochester, MN, United States;
  12. 12 Taussig Cancer Center - Cleveland Clinic, Cleveland, OH, United States;
  13. 13 City of Hope National Medical Center, Duarte, CA, United States;
  14. 14 Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States;
  15. 15 University of British Columbia, Vancouver, BC, Canada;
  16. 16 Mayo Clinic, Scottsdale, AZ, United States;
  17. 17 University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, United States;
  18. 18 Independent Consultant, San Francisco, CA, United States;
  19. 19 Multiple Myeloma Research Consortium, Norwalk, CT, United States;
  20. 20 Onyx Pharmaceuticals, Inc., South San Francisco, CA, United States;
  21. 21 Mount Sinai Medical Center, New York, NY, United States
  1. * Corresponding author; email: dsiegel{at}hackensackumc.org

To view this item, select one of the options below

If you already have a subscription, you may gain access using your ASH username and password.

Sign In for Institutional Administrators

If you are a Librarian or institutional account administrator you can use this link to manage your account and view usage reports.

 

Purchase Short-Term Access

Pay per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00.
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

OpenAthens Users

Log in through your institution

Sign Up

Subscribe to the Journal - Subscribe to the print and/or online journal.

Access for Patients

Access for Patients - Patients desiring access should contact the journal.